沙利度胺治疗中重度寻常型银屑病的疗效评价及对患者血清VEGF和bFGF的影响

Efficacy of thalidomide in the treatment of psoriasis vulgaris and influence on VEGF and bFGF

目的:评价沙利度胺治疗中重度寻常型银屑病的疗效并明确对血清血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF)的影响。方法:30例中重度寻常型银屑病患者口服沙利度胺100 mg/次,每日2次,治疗8周。治疗前后采用银屑病皮损面积和严重程度指数评分标准(PASI)进行疗效评定。采用酶联免疫吸附试验(ELISA)测定患者治疗前后血清VEGF和bFGF水平。结果:30例中重度寻常银屑病患者有效率为60.00%;治疗后血清VEGF和bFGF水平明显低于治疗前(P<0.01);银屑病患者血清VEGF、bFGF水平与PASI评分呈正相关(均P<0.01)。结论:沙利度胺治疗中重度寻常型银屑病有一定疗效,其作用机制可能与抑制血清VEGF和bFGF表达有关。

Objective：To assess the efficacy of thalidomide in the treatment of the patients with psoriasis vulgaris and to determine the influence on the level of serum VEGF and bFGF. Methods：Thirty patients with moderate to severe psoriasis vulgaris were treated with oral thalidomide, 100 mg once, twice a day for 8 weeks. The efficacy of treatment was assessed with PASI. The level of VEGF and bFGF in the patients were detected by ELISA before and after treatment. Results：The effective rate of the treatment was 60.00%. The serum level of VEGF and bFGF after treatment were significantly lower than those before the treatment （ P〈0.01） . The se-rum level of VEGF and bFGF was positively correlated with PASI scores （ P〈0.01） . Conclusion：Thalidomide is effective in the treatment of moderate to severe psoriasis and the mechanism may be through inhibiting the serum expression of VEGF and bFGF.